Other alopecia areata
Methodology & AI Transparency ⓘ
Other alopecia areata Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Other alopecia areata is an ICD-10-CM indexed diagnosis (L63.8) within Hair Loss, Alopecia & Scalp Conditions.
- 2 Real-world patient consensus: Mapped to Hair Loss, Alopecia & Scalp Conditions under ICD-10-CM L63.8 for Other alopecia areata clinical workups.
- 3 Typical cash cost range: Primary evaluation for Other alopecia areata incorporates nutritional/endocrine lab panel in Other alopecia areata (L63.8: (ferritin) and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Other alopecia areata monitoring tracks 25-Hydroxy Vitamin D in Other alopecia areata (L63.8: & Zinc) toward 25(OH)D 45 – 70 ng/mL (L63.8).
Ask our AI Specialists anything about Other alopecia areata
What Is Other alopecia areata?
Other alopecia areata is an ICD-10-CM indexed diagnosis (L63.8) within Hair Loss, Alopecia & Scalp Conditions. Clinical evaluation centers on nutritional/endocrine lab panel in Other alopecia areata (L63.8: (ferritin) alongside serial 25-Hydroxy Vitamin D in Other alopecia areata (L63.8: & Zinc) tracking (25(OH)D 45 – 70 ng/mL (L63.8)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Other alopecia areata (L63.8) center on dihydrotestosterone (DHT)-driven dermal in Other alopecia areata (L63.8: papilla miniaturization). targeted hair & scalp interventions aim to normalize 25-Hydroxy Vitamin D in Other alopecia areata (L63.8: & Zinc).
Common Symptoms & Clinical Signs
- • Presentation of Other alopecia areata (L63.8): discrete smooth circular in Other alopecia areata (L63.8: patches of sudden)
- • Secondary Other alopecia areata clinical sign: thickened, discolored, brittle, in Other alopecia areata (L63.8: or subungually lifting)
- • Symptom flares in Other alopecia areata correlating with 25-Hydroxy Vitamin D in Other alopecia areata (L63.8: & Zinc) deviation outside 25(OH)D 45 – 70 ng/mL (L63.8)
- • Functional hair & scalp impact requiring nutritional/endocrine lab panel in Other alopecia areata (L63.8: (ferritin) evaluation (L63.8)
Other alopecia areata Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L63.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Hair Loss, Alopecia & Scalp Conditions | NLM Clinical Tables |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Other alopecia areata (L63.8: & Zinc) | 25(OH)D 45 – 70 ng/mL (L63.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total/Free Testosterone & in Other alopecia areata (L63.8: DHEA-S (if androgenic)) | Age/sex physiological range (L63.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin [Other alopecia areata L63.8] | 70 – 150 ng/mL (L63.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other alopecia areata
Treatment selection for Other alopecia areata depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other alopecia areata)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
Other alopecia areata Patient Community & “People Like Me” Threads
Filter Other alopecia areata community threads and patient logs by age, biological sex, dosage, and treatment duration.